Otherwise, AP patients initially respond to IM but inevitably relapse with treatment-refractory disease because they acquire other mutations in addition to BCR-ABL amplification or kinase domain mutations [40-42]. This evidence concerns the gene BCR and alkaline phosphatase measurement.